Tracers / [131I]I-T-ZHP1
[131I]I-T-ZHP1
Also written as [I-131]I-T-ZHP1
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- trastuzumab-PNA conjugate (antibody-peptide nucleic acid conjugate)
- Target / mechanism
- HER2, via PNA-mediated pretargeting of trastuzumab PMID 33247180
- Clinical application
- HER2-expressing cancer (radionuclide pretargeting imaging/therapy) PMID 33247180
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 92 ± 5% | more than 95% | T-ZHP1 (trastuzumab-ZHP1 conjugate) Herceptin, Roche, Mississauga, ON | 33247180 2020 Sci Rep radiolabeled with [131I]NaI using direct radioiodination as described earlier — The radiochemical yields were 92 ± 5% and 90 ± 7% for T-ZHP1 and CA, respectively. |
Need this precursor?We can point you to suppliers for [131I]I-T-ZHP1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33247180. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33247180: 'T-ZHP1 (trastuzumab-ZHP1 conjugate)'.